<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03777969</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZX10302204-001</org_study_id>
    <nct_id>NCT03777969</nct_id>
  </id_info>
  <brief_title>Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients</brief_title>
  <official_title>Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Choutu Technology Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi Hisky Medical Technologies Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed after 1 to 3
      years of antiviral therapy are enrolled. All the patients will receive original antiviral
      treatment for the following 3 years. Patients will be assessed at baseline and at every six
      months for blood count, liver function test, alpha fetoprotein (AFP), prothrombin time, liver
      ultrasonography, liver stiffness measurement (LSM), Hepatitis B virus (HBV) DNA and HBV
      serological markers. HBV-related endpoint events, including cirrhosis decompensations
      (ascites, esophageal variceal bleeding and hepatic encephalopathy), hepatocellular carcinoma
      (HCC), liver transplantation and liver-related death, will be collected during follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HBV-related clinical endpoint events, including liver decompensations (ascites, esophageal variceal bleeding and hepatic encephalopathy), HCC, liver transplantation and liver-related death</measure>
    <time_frame>1 to 2.5 years</time_frame>
    <description>Incidence of HBV-related clinical endpoint events during follow-ups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predicted probability of HBV-related clinical endpoint events</measure>
    <time_frame>1 to 2.5 years</time_frame>
    <description>The predicted probability is measured by histological prediction model or non-invasive prediction model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicted probability of HBV-induced fibrosis/cirrhosis regression</measure>
    <time_frame>1 to 2.5 years</time_frame>
    <description>The predicted probability is measured by histological prediction model or non-invasive prediction model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HBV-induced liver fibrosis/cirrhosis regression</measure>
    <time_frame>1 to 2.5 years</time_frame>
    <description>Liver fibrosis regression was defined as decrease &gt;= 1 point by Ishak fibrosis scoring system (range from 0 to 6, higher values represent a worse outcome) or Predominantly Regressive in P-I-R ( predominantly progressive, indeterminate and predominately regressive) score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver biopsy and peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CHB patients with liver biopsy performed after 1 to 3 years of antiviral therapy; or CHB
        patients with antiviral therapy for 1 to 3 years content to be performed liver biopsy at
        enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1: Patients with history of HBV-related clinical endpoint events

        Inclusion Criteria:

          -  No age limit;

          -  Male or female;

          -  Patients with liver biopsy performed after 1 to 3 years of antiviral therapy; patients
             with history of clinical endpoint events (decompensated cirrhosis, hepatocellular
             carcinoma, liver transplantation or liver-related death) after liver biopsy;

          -  Patients with liver biopsy or liver stiffness or aspartate aminotransferase
             (AST)-to-platelet (PLT) ratio index (APRI) before antiviral treatment.

        Exclusion Criteria:

          -  Patients with decompensated cirrhosis (including ascites, hepatic encephalopathy,
             esophageal varices bleeding, hepatorenal syndrome, spontaneous bacterial peritonitis,
             or other complications of decompensated cirrhosis), hepatocellular carcinoma, or liver
             transplantation before liver biopsy;

          -  Patients with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection,
             alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced
             liver injury, or other chronic liver diseases;

          -  Patients with malignant lesion on liver image;

          -  Patients with other uncured malignant tumors;

          -  Patients with severe heart, lung, kidney, brain, blood, neuropsychiatric or other
             organs diseases;

          -  Pregnant or lactating women;

          -  Patients with any other reasons not suitable for the study.

        Group 2: Patients without history of clinical endpoint events

        Inclusion Criteria:

          -  No age limit;

          -  Male or female;

          -  Patients with liver biopsy performed after 1 to 3 years of antiviral therapy; or
             Chronic hepatitis B (CHB) patients with antiviral therapy for 1 to 3 years content to
             be performed liver biopsy at enrollment;

          -  Patients with liver biopsy or liver stiffness or APRI before antiviral treatment;

          -  Agree to be followed up regularly;

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Patients with decompensated cirrhosis (including ascites, hepatic encephalopathy,
             esophageal varices bleeding, hepatorenal syndrome, spontaneous bacterial peritonitis,
             or other complications of decompensated cirrhosis), hepatocellular carcinoma, or liver
             transplantation;

          -  Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease,
             genetic liver disease, drug-induced liver injury, or other chronic liver diseases;

          -  Patients with malignant lesion on liver image;

          -  Patients with other uncured malignant tumors, exclude who were cured;

          -  Patients with severe heart, lung, kidney, brain, blood, neuropsychiatric or other
             organs diseases;

          -  Pregnant or lactating women;

          -  Patients with any other reasons not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong You, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong You, Doctor</last_name>
    <phone>86-010-63139019</phone>
    <email>youhong30@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yameng Sun, Doctor</last_name>
    <phone>86-010-63138665</phone>
    <email>sunyamenggo@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Zhao, Master</last_name>
      <phone>13811398627</phone>
      <email>sally2004@126.com</email>
    </contact>
    <investigator>
      <last_name>Wen Xie, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong You, Doctor</last_name>
      <phone>13521130181</phone>
      <email>youhong30@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yameng Sun, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoning Wu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongpeng Chen, doctor</last_name>
      <phone>13924203581</phone>
      <email>cyp@smu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yongpeng Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi Hisky Medical Technologies Co., Ltd.</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinxin Zhang, Doctor</last_name>
      <phone>+86-21-64370045</phone>
      <email>zhangx@shsmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xinxin Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenghai Liu, Doctor</last_name>
      <email>chenghailiu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Chenghai Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hangzhou Choutu Technology Co.,Ltd.</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hong You</investigator_full_name>
    <investigator_title>Vice-Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Liver fibrosis/cirrhosis</keyword>
  <keyword>HBV-related endpoint events</keyword>
  <keyword>Precise prediction model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

